Ocular Therapeutix (OCUL +30.7%) jumps on almost an 8x surge in volume in reaction to preliminary Q4 results,
Q1 guidance and interim data from a Phase 1 clinical trial evaluating
eye implant OTX-TKI in patients with wet age-related macular
degeneration.
Gross product revenue in Q4 was $2.3M (+172%
sequentially), including $1.6M in Dextenza (dexamethasone ophthalmic
implant) sales (+433% sequentially).
Q1 guidance calls for Dextenza sales of $2.4M –
2.6M, a bit conservative considering the 50% increase in Key Account
Managers in November 2019.
Preliminary data from the early-stage study showed
a favorable safety profile and a decreases in intraretinal and/or
subretinal fluid in some participants who received the higher dose.
https://seekingalpha.com/news/3548608-ocular-therapeutix-up-31-on-dextenza-ramp-encouraging-data-on-eye-implant
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.